Skip to main content
OpenTrials
Completed

NCT Number: NCT02036619

The Belgian Diabetes in Pregnancy Study: BEDIP-N Study

The General hypothesis is that the IADPSG screening strategy for gestational diabetes (GDM) will lead to an important increase in the work load and the prevalence of GDM in Belgium but that this might not be cost effective concerning the prevention of adverse pregnancy outcomes. The risk to develop type 2 diabetes postpartum will probably be lower than for women diagnosed with the two-step screening strategy.

In this prospective multicentric cohort study, women will be universally screened for pregestational diabetes and GDM at the first prenatal visit during the first trimester by measuring the fasting plasma glucose. In the second trimester, women without diagnosis of diabetes or GDM in the first trimester, will be universally screened for GDM using the 50g glucose challenge test (GCT) and the 75g oral glucose tolerance test (OGTT) with the IADPSG criteria for GDM. Diagnosis of GDM will be based on the 75g OGTT.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

Female

Study type

Observational

Primary location

OLV Aalst, Aalst, Belgium

Loading trial locations.

About this study

Accurate data on the prevalence of gestational diabetes (GDM) are lacking in Belgium and the current practice for screening for GDM varies across different centers. The discrepancy in recommendations is due to the lack of data based on research in our population concerning the best screening strategy for pregestational diabetes in early pregnancy and the lack of data on the best screening strategy for GDM. A substantial number of centers in Belgium already use the IADPSG screening strategy although not always a an universal screening strategy or not always as an one-step screening strategy.

The General hypothesis is that the IADPSG screening strategy will lead to an important increase in the work load and the prevalence of GDM in Belgium but that this might not be cost effective concerning the prevention of adverse pregnancy outcomes. The risk to develop type 2 diabetes postpartum will probably be lower than for women diagnosed with the two-step screening strategy.

In this prospective cohort study, women will be universally screened for pregestational diabetes and GDM at the first prenatal visit during the first trimester by measuring the fasting plasma glucose. GDM will be defined as a fasting plasma glucose ≥100-125mg/dl. This will allow to identify the most important risk factors for the development of GDM.

In the second trimester, women will be universally screened for GDM using the 50g glucose challenge test (GCT) and the 75g oral glucose tolerance test (OGTT)with the IADPSG criteria for GDM. Compared to the IADPSG screening strategy used in normal routine, the 50g GCT will be an extra test specific for the study. Diagnosis of GDM will be based on the 75g OGTT. Participants and researchers will therefore be blinded for the result of the GCT. The results of the GCT test will be used at the end of the study for research purposes only. The use of a GCT as an universal screening tool in a two-step approach with the use of the 75g 2-hour OGTT with the IADPSG criteria only if the GCT is abnormal, is not yet validated and will be evaluated in the study, since this could be a practical solution. Differences in GDM prevalence and pregnancy outcomes will be analyzed using different diagnostic criteria based on the 75g OGTT: the Carpenter & Coustan criteria, the IADPSG criteria, and threshold values if diagnostic criteria would be based on an odds ratio of 2.0. The evaluation of different screening strategies and different diagnostic criteria will allow to explore the most cost effective methods for identifying women at risk for adverse pregnancy outcomes and at high risk for the development of type 2 diabetes after pregnancy. By using a multivariable risk estimation model based on the most relevant clinical risk factors and biochemical measures for GDM in our own population, the aim is to develop a simple and cost effective screening algorithm.

This study will also allow to evaluate the best short-term follow up strategy postpartum for women with a previous history of GDM. Different screening tests will be used three months postpartum: a fasting plasma glucose, Hba1c and 75g OGTT.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women between 18-45 years,
  • singleton pregnancy
  • between 6-13 weeks of pregnancy
  • the delivery has to be planned in the hospital where the study is performed.

Exclusion criteria

  • < 18 years or > 45 year
  • multiple pregnancy
  • known diabetes or taking metformin
  • chronic treatment with corticoids
  • signs of a miscarriage
  • Chronic medical condition: uncontrolled hypertension, severe heart disease, severe chronic liver disease, severe chronic kidney disease, chronic infection (such as HIV or hepatitis)
  • bariatric surgery
  • delivery is planned in another center than the screening
  • a normal follow up and treatment during pregnancy will not be possible (due to incompliance, psychiatric problems, severe communication problems…)
  • participating in another study with any medication or intervention ( including life style intervention) up to 90 days before the start of the study

Treatment and study plan

Primary outcomes

  1. Difference in GDM prevalence between the 2-step and 1-step IADPSG screening strategy

    Time frame: 2 years

    Evaluation of the difference in GDM prevalence between the 2-step (50 glucose challenge test followed by a 75g OGTT) and 1-step IADPSG (directly 75g OGTT) screening strategy.

  2. The difference in macrosomia rate between GDM and non-GDM groups according to the IADPSG criteria.

    Time frame: 2.5 years

  3. The number of participants with obesity, a history of GDM, a history of prediabetes or a family history of diabetes in women with and without GDM

    Time frame: 2 years

    risk factors will be analyzed such as ethnicity, maternal age, maternal BMI, family history of diabetes, history of GDM, history of impaired glucose regulation and socio-economic factors

  4. The glucose tolerance status 3 months postpartum in women with recent GDM.

    Time frame: 3 years

    Evaluation of rate of diabetes and prediabetes 3 months postpartum in women with recent GDM.

Secondary outcomes

  1. Differences in rate of large for gestational age baby's, pre-eclampsia and caesarean section between GDM and non-GDM groups according to different diagnostic criteria

    Time frame: 2.5 years

    evaluation according different diagnostic criteria used (IADPSG criteria, the Carpenter & Coustan criteria and with the diagnostic criteria based on an odds ratio of 2.0)

  2. The sensitivity and the specificity of the 50g glucose challenge test as a universal screening tool in a two-step approach with the use of the 75g 2-hour OGTT

    Time frame: 2.5 years

    Evaluation of the value of the 50g glucose challenge test as a universal screening tool in a two-step approach with the use of the 75g 2-hour OGTT with the IADPSG criteria, with the use of the Carpenter & Coustan criteria and with the diagnostic criteria based on an odds ratio of 2.0

  3. Prevalence of pregestational diabetes in early pregnancy

    Time frame: 2 years

    Prevalence of pregestational diabetes before 14 weeks of pregnancy

  4. The number of participants with dyslipidaemia and hypertension in women with and without GDM

    Time frame: 2.5 years

    BMI, lipid profile, blood pressure, adiponectin, leptin and Hs-CRP

  5. Percentage body fat and c-peptide on cord blood in the offspring at birth of mothers with diabetes/GDM and without diabetes/GDM.

    Time frame: 3 years

    birth weight, length, head circumference, skinfold thickness and c-peptide on cord blood

  6. The prevalence of MODY-2 in women with a fasting plasma glucose ≥92mg/dl in early and late pregnancy

    Time frame: 3 years

  7. The prevalence of women with a fasting plasma glucose ≥ 92-99mg/dl in early pregnancy to have a normal 75g OGTT between 26-28 weeks of pregnancy.

    Time frame: 2.5 years

Sponsors and collaborators

Lead sponsor

Universitaire Ziekenhuizen KU Leuven

Other

Collaborators

  • AstraZeneca
  • FWO clinical doctoral scholarship
  • Merck Sharp & Dohme LLC
  • Novartis
  • Novo Nordisk A/S
  • Sanofi
  • The National Lottery

Registry information

Official study title

Prospective and Multi-centric Study on Diabetes During Pregnancy in Belgium

Acronym: BEDIP-N

Important dates

Study start
2014
Primary completion
2017
Study completion
2018
First posted
Jan 15, 2014
Registry last updated
May 11, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.